Method for identification of patients with first attacks of acute porphyria

FIELD: medicine.

SUBSTANCE: clinical and laboratory criteria: gender, age - are determined. History data is determined: intake of new drugs, alcohol, newly diagnosed liver pathology, disease symptoms in the premenstrual period, emotional instability. The presence of tachycardia, arterial hypertension, dyskinesia of the gastrointestinal tract: constipation or diarrhea, nausea and vomiting, pain in the abdomen - are also determined. Presence of urine dark in daylight is identified. The presence of muscle weakness in the form of tetraparesis, paraparesis, hemiparesis is determined. The presence of a violation of urination and defecation control; violation of sensitivity are revealed as well, body temperature, appearance of hallucinations and delirium, epileptiform seizures are determined. The presence of dyspnea, facial nerve paresis, bulbar disorders is determined. The presence of leukocytosis of more than 12*109/l and ESR of more than 30 mm/h, bilirubinuria, erythrocyturia, excess reference values of uric acid, urea and hyponatremia are revealed as laboratory indicators. Clinical and laboratory criteria are scored in accordance with Table 1 contained in the description. The derived points are summed up. If the score is less than 5 - acute porphyria is unlikely, from 5 to 15 - porphyria is possible, more than 15 - acute porphyria is highly probable.

EFFECT: method allows to effectively and quickly identify patients with acute porphyria due to comprehensive assessment of the most significant indicators.

2 dwg, 3 tbl, 3 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: saliva of affected child is analysed by method of infrared spectroscopy, value of ratio of peak height with maximum at 1070 cm-1 to peak height with maximum 1025 cm-1 is calculated. If value of ratio is in range from 1.1 to 1.9 nonspecific ulcerative colitis is diagnosed, and if value of said ratio is from 2.0 to 4.6 Crohn's disease is diagnosed.

EFFECT: invention ensures less invasive and simpler differential diagnostic of NUC and Crohn's disease in children, ensures simplification and acceleration of diagnosis determination.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed.

EFFECT: application of the claimed method makes it possible to increase accuracy in diagnostics being simple in realisation.

2 ex

FIELD: medicine.

SUBSTANCE: method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less.

EFFECT: invention enables studying the responses of female humoral immune factors to male antigens and evaluating a risk of miscarriage, early spontaneous abortions and missed miscarriages.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a high-sensitivity method for measuring the amount of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts. The high-sensitivity method for measuring the amount of glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts is characterised by the fact that a mixture of individual's blood plasma with methanol or ammonia water in the specific concentration is introduced into a solid phase having the reverse-phase distribution function and the anion exchange function; the solid phase is then washed with a cleaning fluid that is a single-component fluid or a mixed fluid of at least two components specified in a group containing water, alkali, alcohol and acetonitrile. That is followed by elution from the solid phase in acid alcohol specified in formic acid - methanol or formic acid - ethanol; that is followed by the stage of measuring glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts by liquid chromatography - mass spectrometry or liquid chromatography - mass spectrometry/mass spectrometry.

EFFECT: high-sensitivity method enables detecting and measuring the amounts of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts.

4 dwg, 17 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises selection of only living, mature females of Trichuris vulpis from colon, blind gut of wild and/or domestic carnivorous animals infected spontaneously with whipworms in the study with helminthological methods when autopsy, into separate tubes with officinal isotonic solution (0.9%) of sodium chloride (solutio Natrii chlorati isotonica) and the exposure of the tubes with the females of Trichuris vulpis at t = 37.5-39°C for 5 hours under conditions of a thermostat.

EFFECT: method enables to select a large amount of fertilised eggs of T vulpis, not contaminated with particles of undigested feed, the particles of destroyed tissue of genitals of female of T vulpis and secondary bacterial microflora.

2 ex

FIELD: medicine.

SUBSTANCE: patient's peripheral venous blood is recovered to analyse genetic polymorphisms of coagulation factors VII 10976G/A FVII. A birth weight of a newborn of a woman delivering not for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6123.431-25.579x1+0.267x2+205.739x3, wherein y is an anticipated newborn's weight, x1 is a female's height in centimetres; x2 is an infant's weight at the previous delivery in grams, x3 is a genetic version of 10976G/A FVII locus with x3=1 for 10976 GG FVII genetic type, x3=2 for 10976 GA and 10976 AA FVII genetic types. A birth weight of a newborn of a woman delivering for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6278.037-21.739x1+232.170x2, wherein x1 is a female's height in centimetres; x2 is a genetic version of 10976G/A FVII locus with x2=1 for 10976 GG FVII locus, x2=2 for 10976 GA and 10976 AA FVII genetic types.

EFFECT: invention enables improving the prevention and treatment of the pregnancy complications.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: pre-operative fasting venous blood 1 ml is sampled at room temperature 20-24°C into an anticoagulant-free vacuum system (test tube). The test tubes are delivered in a sealed container at temperature 2-8°C for 2 hours to a laboratory for immunoenzyme assay and analysed to determine anti-thyroid stimulating hormone receptor antibodies. If the antibody level is 1.5 units/l or more, a thyroidectomy is performed, whereas the antibody level of less than 1.5 units/l requires performing a subtotal thyroid resection according to standard techniques.

EFFECT: invention enables reducing a probability of recurrent thyrotoxicosis in the patients after subtotal thyroid resection.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of a risk of early microvascular complications in the children suffering from type 1 diabetes mellitus. The substance of the method consists in defining a duration of the diseases in years, the patient's age in years, a desquamated endothelial cell count, high-density lipoprotein cholesterol, total cholesterol, triglycerides, atherogenic index, glycohaemoglobin, average daily glycaemic level; making a linear regression analysis and calculating a risk ratio (R) of early microvascular complications in the children suffering from type 1 diabetes mellitus by formula. If the risk ratio is ≥1, the high risk of early microvascular complications during one year is predicted; the ratio < 1 shows the low risk of microvascular complications during one year.

EFFECT: using the declared method enables increasing the prediction accuracy of microvascular complications in the children with type 1 diabetes mellitus.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for patient's status monitoring. A method for setting a time-varying physiological parameter warning signal involves patient's controlled parameter monitoring, comparing the controlled parameter to an initial cut-off criterion, varying the cut-off criterion temporarily by a cut-off criterion of deterioration after the therapy, and then after a certain period of time, by the cut-off criterion after the administration. The time allowed involves comparing the controlled parameter to the cut-off criterion of deterioration, and after the time allowed - to the cut-off criterion after the administration. The warning signal is initiated in response to the controlled parameter of one or more initial cut-off criteria, the cut-off criterion of deterioration and the cut-off criterion after the administration. The group of inventions also refers to a machine-readable carrier with software for implementing the method and to a system for user warning on the controlled parameter variation.

EFFECT: group of inventions provides higher accuracy and rate of assessing the patient's status according to the conducted therapy.

15 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention can be used for the purpose of the early prediction of cystic periventricular leukomalacia (PVL) in the newborns with very low (VLBW) or extremely low body weight (ELBW). Substance of the method: the newborns with VLBW and ELBW on the 3rd-7th day of life are examined to assess the perinatal medical history, namely the presence of chorioamnionitis and amniotic fluid nature, 5th minute Apgar score, the absence of prolonged artificial pulmonary ventilation, a severity of respiratory distress syndrome, the presence of pneumonia, sepsis, convulsive disorder, anaemia, laboratory signs of the systemic inflammatory reaction, average values of carbon dioxide, anionic bicarbonate and base deficiency in capillary blood, interleukine-6 and receptor interleukine-1 antagonist in venous blood serum. Each sign is assigned with a prognostic coefficient (PC). That is followed by determining total PC, and it is expected cystic PVL that is decided for if total PC is at least (+)9.5, whereas no cystic PVL is expected if total PC is (-)9.5 or less.

EFFECT: invention provides the early (for the first 7 days of life) prediction of cystic periventricular leukomalacia in the most susceptible category of patients that are children with very low and extremely low birth weight.

6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: clinical dental health parameters following the endodontic treatment (Cl parameter) expressed in the quantitative equivalent according to table 3, are recorded. The X-ray periapical tissue health parameters following the endodontic treatment (Rtissue parameter) expressed in the quantitative equivalent according to table 4, are recorded.The X-ray root filling health parameters following the endodontic treatment (Rfilling parameter) expressed in the quantitative equivalent according to table 5, are recorded. In questionable cases, the recording procedure involves a higher rate of the estimation scale, and for multirooted teeth - the highest rate specified; each following root filling health parameter and its assessment criterion is secondary from the previous one depending on a degree of risk of potential post-endodontic complications and arranged in the ascending order, thereby characterising an increase of a therapeutic defect rate, except for the first assessment criteria of each of the parameters of a quantitative aspect of the X-ray filling health with 1 point assigned to describe the ideal clinical outcome for the given parameter. A complex index of the endodontic treatment expressed in points is calculated by formula: CIET = Cl+Rtissue+ΣRfilling, wherein CIET is the complex index of the endodontic treatment; Cl is the quantitative characteristics of the clinical dental health following the endodontic treatment; Rtissue is the quantitative characteristics of the X-ray periapical tissue health following the endodontic treatment; ΣRfilling is a total score derived in accordance with the criteria of the quantitative characteristics of the X-ray root filling health following the endodontic treatment. The clinical outcome is analysed on a basis of theoretical evaluation of numerical ranges of accepted values of the complex index of the endodontic treatment enabling to specify the therapeutic approach to the patient. The complex index less than 12 points testifies to adequate leak resistance of the root filling; pathological changes in the periapical tissues are absent; the tooth does not need to be treated; the prediction is considered to be favourable. If the range is 13-19 points, the root filling occurs to seal the root canal inadequately; the risk of periapical complications is minimised; the 6-24-month case follow-up is recommended. The range of 20-37 points shows the unsatisfactory leak resistance of the root filling; the high probability of post-endodontic complications is stated; the recurrent endodontic manipulation is recommended; the prediction is open to question. If the index reaches 37 points and more, the surgical management is recommended.

EFFECT: by additional quantitative characteristics of the clinical and X-ray periapical tissue and root filling health, the method enables characterising the quality of the therapeutic outcomes in the nearest and remote period, and specifying the indications for a certain method of treating.

8 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dentistry, and can be used in diagnosing body sensitivity to dental materials. A challenge test involving a 2-hour contact of a sampling material and an oral mucosa is conducted. The state of the oral mucosa microvasculature is assessed by computed biomicroscopy. A diameter of a capillary arteriolar domain, a diameter of a capillary venular domain, a mean diameter of a capillary, a diameter of gathering venules, a functional capillary density are measured. If one of the relevant parameters tends to vary at a value, which is at least 1.5 times as much as a parameter variation error, a high sensitivity to the dental materials is diagnosed.

EFFECT: technique enables providing the more objective and reliable procedure applicable to diagnose the sensitivity by using the computed biomicroscopy for studying the tissue changes and selecting the best assessment criteria.

6 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology. A method involves estimating a compliance level on the basis of 20 test questions of the compliance rating scale applicable for the patients suffering hypertensive disease; each question has three selective answers coded from 1 to 3 points; the patient either fills in the scale independently, or ticks the answers to the questions being read out by the doctor. The result interpretation involves the total score for all the questions: 51-60 means a high compliance level; 41-50 shows a medium compliance level, whereas 40 points or less stand for a low compliance level.

EFFECT: estimating the compliance level and objectifying the results in points in the patients with hypertensive disease of the 1st-2nd stage, in arterial hypertension of the 1st-3rd degree by means of the specifically developed rating scale applicable to estimate the compliance in the patients suffering hypertensive disease.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, functional diagnostics and can be used for preclinical, predoctoral examination, assessment of the functional state of body organs and systems, and pre-diagnosis. The method involves measuring electrical conductivity (EC) of 24 representing points of 12 symmetrical meridians, determining an arithmetic mean (AM) value of these measurements and specifying a corridor of permissible values for this patient, to which the derived values are compared in order to assess the functional state of the patient's body. That involves using the following criteria: a ratio of total ECs of Yin meridian points to total ECs of Yang meridian points, a ratio of total ECs of arm points to total ECs of leg points, a ratio of total ECs of left-side points to total ECs of right-side points. ECs are measured at voltages 5V, and/or 9V, and/or 12V. If the measurements are taken at 9V, the measured ECs are re-calculated by formula: I new=9/(29/I measured-0.1)*Coeff, (I); if the measurement process is performed at 12V, the measured values are re-calculated by formula: I new=9/(29/I measured-0.1)*Coeff, (I); and at 5V: I new=1 measured*Coeff, (III), wherein in (I), (II) and (III) respectively: I new is the re-calculated EC; I measured is the measured EC; Coeff is a correction coefficient taking into account a meridian conductivity heterogeneity. The re-calculated values are transformed into adjusted ones by formula: I adjusted=I new/I mean, wherein: I adjusted is the adjusted EC; I new is the non-adjusted re-calculated EC; I mean is the arithmetic mean value of all the 24 measurements. That is followed by delimiting an individual normal corridor for this patient depending on the preset diagnostic sensitivity S and a width of corridor of the permissible EC values Wpv. The Wpv represents a range of EC values measured in this patient, whereas the diagnostic sensitivity S is specified depending on selecting the patients with a certain disease. Delimiting the individual normal corridor for this patient is ensured by measuring intermediate coefficients for lower Kl and upper Ku corridor limits respectively: Kl=1-(1-S)*Wpv/2.1 and Ku=1+(1-Kl)*1.1. Lower L and upper U limits of the individual normal corridor are determined: L=Kl* I mean and U=Ku* I mean. That is followed by comparing I adjusted to the derived limits of the individual normal corridor.

EFFECT: method provides high accuracy of the individual diagnosis.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: senior guinea pigs are exposed to optical light generated by light emitting diodes or fluorescent tubes at a colour temperature of 4,500 K within the wavelength region of 360-460 nm for various time distances. The exposure is assessed by functional activity indices of neutrophilic granulocytes and a mononuclear cell count.

EFFECT: using the method requires no expensive equipment, critical chemicals; it is of a particular importance for evaluating the biological safety of new artificial light sources embedded into a light-colour medium; it provides expanded information on biological effects of optical light.

3 tbl

FIELD: medicine.

SUBSTANCE: method involves specifying the patient's age in years, measuring a left atrium diameter in millimetres, assessing the anti-arrhythmic therapy provided and determining a degree of aortic and mitral incompetence. The produced values are used to calculate a risk (R) of recurrent atrial fibrillation following a radiofrequency ablation procedure by original formula. If the derived value R is more than 0.5, the development of recurrent atrial fibrillation is predicted to follow the radiofrequency ablation procedure; the value R of 0.5 or less shows no risk of recurrent atrial fibrillation following the radiofrequency ablation procedure.

EFFECT: higher prediction accuracy.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment, namely to equipment for visualisation of physiological data. Method of monitoring physiological parameters contains stages at which physiological parameters are measured periodically or aperiodically by at least one electronic sensor, with each measured value of physiological parameter having corresponding medical expiry date, determined and continuously visualised are: the last measured value of each measured physiological parameter and its designation, medical expiry date for each measured value of physiological parameter, which represents preliminary specified maximal time, during which value of physiological parameter is visualised, remaining medical term to expiry date of each measured value of physiological parameter for inquired time moment is determined, for each measured physiological parameter with non-zero remaining time period before expiry date determined and visualised on display are: the last measured value of physiological parameter, its designation and indication of remaining medical time period before expiry date in form of indicating the number of days, hours, minutes or seconds, during which reading is visualised, or indication of amount of time before visualisation of the following reading, with removal of reading from display in real time after preliminary configured medical term before expiry date finishes, absence of image is replaced with symbol, showing absence of current reading. Method is realised with application of machine-readable carrier, containing programme, recorded on it, and device for visualisation of data values and designations of patient's physiological parameters, which contains electronic sensors for periodical of aperiodical measurement of values of physiological parameters, processor, programmed for determination of the last measured physiological parameter and display device control.

EFFECT: application of invention makes it possible to increase rapidity of determination of data remoteness of the screen.

8 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: "orthopaedic index" is calculated as a sum of three values. The first value is derived by conducting densitometry, and points are assigned according to its findings: 1 point for norm, 2 points for osteopenia, 3 points for osteoporosis, and 4 points for severe osteoporosis. The second value is derived by means of Charlson comorbidity index; 0-2 points according to the Charlson comorbidity index scale correspond to 1 point of the second value; 3 points of the Charlson comorbidity index scale are 2 points of the second value; 4 points of the Charlson comorbidity index scale show 3 points of the second value, while 5 points and more of the Charlson comorbidity index scale correspond to 4 points of the second value. The third value is determined by assessing the quality of life as per the scales SF-36; 0-200 points according to the scales SF-36 correspond to 4 points of the third value; 201-400 points of the scale SF-36 show 3 points of the third value; 401-600 points of the scales SF-36 provide 2 points of the third value, and 601-800 points correspond to 1 point of the third value. Total score is deriving by summing up the three values to determine "the orthopaedic index": I - 1-3 points, II - 4-6 points, III - 7-9 points, IV - 10-12 points. The form of treatment is defined: the patients with index I have the endoprosthesis replacement with endoprostheses with a shortened leg of the femoral component, the greater diameter of the head (36 mm or more); the patients with index II have the endoprosthesis replacement with cementless anchored total endoprostheses; the patients with index III have the total hip replacement with cemented endoprostheses; the patients with index IV have the endoprosthesis replacement with cemented anchored bipolar endoprostheses.

EFFECT: through assessing the available factors influencing the postoperative period, prosthesis anchoring in its bed, potential endoprosthesis rejection, functional effect and potential aggravation of comorbidities, the method can improve functional outcomes, reduce the risk of endoprosthesis loosening and the risk of recurrent operations.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to devices for medical monitoring. The method contains stages at which: a packet (7) of data about a patient is transmitted from a device (10) for patient monitoring to the central server (12); a message (72) with acknowledgement (ACK), transmitted by the central server (12) in response to receiving by the central server (10) of the transmitted packet (70) of data about the patient, with a message with acknowledgement containing a time stamp, provided from the central server (12) clock (46), indicating the time and date, when the central server (12) received the packet (70) of the patient's data; the message time stamp (72) with ACK is compared with the current time of the clock (28) of the patient monitoring device (10); and if the difference between the current time of the clock (28) of the patient monitoring device (10) and the time stamp (74) with ACK is larger than the first preliminarily determined time, the clock (28) is synchronised in accordance with the time and date in the time stamp (74) in the message (72) with ACK.

EFFECT: provision of control of the time synchronisation interface.

13 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: non-invasive examination of vessels is performed by means of a probe, installed on the skin surface in the projection of a vessel, by a method of optic coherent (OC) tomography, tomograms, obtained without compression test and OC tomograms under conditions of the compression test by the displacement of tissues by the probe by 1 mm towards the visualised vessel, are analysed. Compressibility of the vessel, tissues and formations and uniformity of the vessel configuration change under compression are estimated on the images. If a non-uniform and/or incomplete compressibility and a non-uniformity of the vessel configuration change are detected, microangiopathy is identified.

EFFECT: method ensures the high accuracy and objectivity of non-invasive diagnostics of the condition of microvasculature, in particular, the presence of intra-vascular formations, including differential diagnostics of vasculopathy due to the identification of particular criteria for the determination of pathological changes.

5 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out ultrasonic scanning examination of subclavian artery over its whole extent in physiological arm position with arterial blood pressure being measured in the middle one third of the arm. Next, when applying compression tests, blood circulation parameters variations are recorded in distal segment of the subclavian artery with arterial blood pressure being concurrently measured. Three degrees of superior thorax aperture syndrome severity are diagnosed depending on reduction of linear blood circulation velocity and arterial blood pressure compared to their initial values. Mild one takes place when linear blood circulation velocity reduction reaches 40% and arterial blood pressure 20% of initial level, moderate one when linear blood circulation velocity reduction reaches 70% and arterial blood pressure 50% and heavy one when linear blood circulation velocity reduction is greater than 70% of initial level and arterial blood pressure is greater than 50% to the extent of no blood circulation manifestation being observed in the subclavian artery.

EFFECT: high accuracy of diagnosis.

Up!